RB1 and cancer: Given the possible codeletion of RB1 and NUDT15 in a variety of cancer types, a thiopurine‐based collateral lethality strategy could be practical to precisely treat cancer patients with somatic deletion at the RB1–NUDT15 locus, which is also a potential drug repurposing strategy for thiopurine in cancer treatment.